Shares of Hims & Hers Health ( HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...

Novo Nordisk (NYSE: NVO) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (NYSE: HIMS). This ...

The U.S. FDA declared that Novo Nordisk's weight loss and diabetes drugs, Ozempic and Wegovy, are no longer in shortage.

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

It should be noted that Hims and Hers stock had jumped 43% in the week prior to the announcement, which has been attributed to the acquisition of Tybre Labs and a controversial Super Bowl ad.

Despite the recent downturn, Hims & Hers Health's stock had seen a significant increase of 43% in the past five days prior to the FDA's announcement. The end of the drug shortage and subsequent ...